{"DataElement":{"publicId":"3613600","version":"1","preferredName":"Disease or Disorder Atypical Ductal Breast Hyperplasia Atypical Lobular Breast Hyperplasia Lobular Breast Carcinoma In Situ Ductal Breast Carcinoma In Situ Invasive Breast Carcinoma Personal Medical History Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether there is a personal history of atypical ductal breast hyperplasia (ADH), atypical lobular breast hyperplasia (ALH), lobular breast carcinoma in situ (LCIS), ductal breast carcinoma in situ (DCIS), or invasive breast cancer.","longName":"3613599v1.0:3506068v1.0","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"3613599","version":"1","preferredName":"Disease or Disorder Atypical Ductal Breast Hyperplasia Atypical Lobular Breast Hyperplasia Lobular Breast Carcinoma In Situ Ductal Breast Carcinoma In Situ Invasive Breast Carcinoma Personal Medical History","preferredDefinition":"information related to a personal history of atypical ductal breast hyperplasia (ADH; a neoplastic process that arises from the terminal ductal lobular unit of the breast parenchyma), atypical lobular breast hyperplasia (ALH; lobular neoplasia characterized by lobular epithelial proliferation that does not completely fill the lobular unit of the breast), lobular breast carcinoma in situ (LCIS; a non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina), ductal breast carcinoma in situ (DCIS; a carcinoma entirely confined to the mammary ducts), or invasive breast cancer (a carcinoma that infiltrates the breast parenchyma).","longName":"2404658v1.0:3613597v1.0","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3613597","version":"1","preferredName":"Atypical Ductal Breast Hyperplasia Atypical Lobular Breast Hyperplasia Lobular Breast Carcinoma In Situ Ductal Breast Carcinoma In Situ Invasive Breast Carcinoma Personal Medical History","preferredDefinition":"A benign (not cancer) condition in which there are more cells than normal in the breast lobules and the cells look abnormal under a microscope. Having atypical lobular hyperplasia increases the risk of breast cancer.:A benign (not cancer) condition in which there are more cells than normal in the breast lobules and the cells look abnormal under a microscope. Having ALH increases the risk of breast cancer.:A non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina.  The overall lobular architecture is preserved.  It is frequently multifocal (90% in some series) and bilateral.  It seldom becomes invasive; however there is an increased risk of infiltrating ductal adenocarcinoma.:A carcinoma entirely confined to the mammary ducts. It is also known as DCIS. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.:A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women. --2003:an account of all medical events and problems a person has experienced.","longName":"3613597v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Atypical Ductal Hyperplasia","conceptCode":"C8436","definition":"A neoplastic process that arises from the terminal ductal lobular unit of the breast parenchyma.  It is usually solitary and confined to a single lobular unit.  It is characterized by the presence of a monomorphic epithelial proliferation in a cribriform, micropapillary, or solid growth pattern.  Focal architectural features of low grade ductal carcinoma in situ are present.  There is an increased risk for development of invasive breast carcinoma.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Breast Atypical Lobular Hyperplasia","conceptCode":"C4730","definition":"Lobular neoplasia characterized by lobular epithelial proliferation that does not completely fill the lobular unit of the breast.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Breast Lobular Carcinoma In Situ","conceptCode":"C4018","definition":"A non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina.  The overall lobular architecture is preserved.  It is frequently multifocal (90% in some series) and bilateral.  It seldom becomes invasive; however there is an increased risk of infiltrating ductal adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Breast Ductal Carcinoma In Situ","conceptCode":"C2924","definition":"A breast carcinoma entirely confined to the mammary ducts. It is also known as DCIS. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Invasive Breast Carcinoma","conceptCode":"C9245","definition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Personal Medical History","conceptCode":"C18772","definition":"A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBE600E8-6367-DD4B-E040-BB89AD43684D","latestVersionIndicator":"Yes","beginDate":"2012-10-12","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-10-12","modifiedBy":"ONEDATA","dateModified":"2012-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBE600E8-6378-DD4B-E040-BB89AD43684D","latestVersionIndicator":"Yes","beginDate":"2012-10-12","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-10-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"5/16/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811953","version":"1","longName":"Disease Description","context":"CTEP"}]},{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"5598962","version":"1","longName":"MDA2014-04-01","context":"DCP"}]}],"AlternateNames":[{"name":"3613599v1.0:3506068v1.0","type":"USED_BY","context":"Alliance"},{"name":"DCP","type":"USED_BY","context":"DCP"}],"ReferenceDocuments":[{"name":"Does the patient have a histo","type":"Preferred Question Text","description":"Does the patient have a history of ADH, ALH, LCIS, DCIS, or invasive breast cancer?","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Biopsy demonstrating atypical hyperplasia, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS)","url":null,"context":"CTEP"},{"name":"DCP Question - 1","type":"Alternate Question Text","description":"In Situ or Invasive Carcinoma","url":null,"context":"DCP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBE600E8-6389-DD4B-E040-BB89AD43684D","latestVersionIndicator":"Yes","beginDate":"2012-10-12","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-10-12","modifiedBy":"MAESKEB","dateModified":"2016-08-25","changeDescription":" Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}